GSK homepage Annual Report
Annual review Downloads
           
  2000   1999  
  Notes £m   £m  
Goodwill 16 170   160  
Intangible assets 17 966   926  
Tangible assets 18 6,642   6,402  
Investments 19 2,544   1,804  
Fixed assets 10,322   9,292  
           
Equity investments 20 171   52  
Stocks 21 2,277   2,243  
Debtors 22 5,399   4,828  
Liquid investments 26 2,138   1,780  
Cash at bank 26 1,283   579  
Current assets 11,268   9,482  
Loans and overdrafts 26 (2,281)   (2,819)  
Other creditors 23 (6,803)   (5,629)  
Creditors: amounts due within one year (9,084)   (8,448)  
Net current assets 2,184   1,034  
           
Total assets less current liabilities 12,506   10,326  
Loans 26 (1,751)   (1,897)  
Other creditors 23 (143)   (147)  
Creditors: amounts due after one year (1,894)   (2,044)  
Provisions for liabilities and charges 24 (1,657)   (1,675)  
Net assets 8,955   6,607  
           
Called up share capital 28 1,556   1,549  
Share premium account 28 30    
Other reserves 30 6,125   3,915  
Equity shareholders’ funds 7,711   5,464  
           
Non-equity minority interest 29 1,039   961  
Equity minority interests 205   182  
Capital employed 8,955   6,607  
           
           
Approved by the Board          
Sir Richard Sykes, Chairman          
22nd March 2001          
           
   
  Back to top
  Updated March 22, 2001 - © 2001-2002 GlaxoSmithKline - All Rights Reserved
Legal Notices
- Privacy Statement